Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 191, Issue 5, Pages 1598-1605Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2004.05.007
Keywords
interferon-gamma; ovarian cancer; cancer immunology; chemotherapy
Categories
Ask authors/readers for more resources
Background: Epithelial ovarian cancer prognosis is improved by the presence of intratumoral CD3(+) T cells; which are known to produce interferon-gamma. We therefore speculated that interferon-gamma expression in ovarian cancer-infiltrating T-lymphocytes might cause better prognosis. Patients and methods: Reverse transcriptase polymerase chain reaction was performed to measure the expression of interferon-gamma and other related genes in normal ovaries (n = 19) and in ovarian cancer specimens (n = 99). Median follow-up of patients was 5.8 years. Results: Interferon-gamma and CD-3 expression did not significantly differ in normal and malignant tissue. Patients with high levels of interferon-gamma expression had significantly longer progression-free and overall survival. Median time to progression was 10 and 29 months for patients with low and high interferon-gamma expression, respectively (P = .039). Corresponding survival times were 29 and 44 months (P < .032). Application of multivariate Cox regression analysis showed interferon-gamma expression to be an independent prognostic factor for progression-free and overall survival. Conclusion: Elevated interferon-gamma expression correlates with improved clinical outcome in patients with ovarian cancer. (C) 2004 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available